Show simple item record

dc.contributor.authorLewis, J.P.
dc.contributor.authorRiaz, M.
dc.contributor.authorXie, S.
dc.contributor.authorPolekhina, G.
dc.contributor.authorWolfe, R.
dc.contributor.authorNelson, M.
dc.contributor.authorTonkin, A.M.
dc.contributor.authorReid, Christopher
dc.contributor.authorMurray, A.M.
dc.contributor.authorMcNeil, J.J.
dc.contributor.authorShuldiner, A.R.
dc.contributor.authorLacaze, P.
dc.date.accessioned2020-07-16T03:45:06Z
dc.date.available2020-07-16T03:45:06Z
dc.date.issued2020
dc.identifier.citationLewis, J.P. and Riaz, M. and Xie, S. and Polekhina, G. and Wolfe, R. and Nelson, M. and Tonkin, A.M. et al. 2020. Genetic variation in PEAR1, cardiovascular outcomes and effects of aspirin in a healthy elderly population. Clinical Pharmacology and Therapeutics.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/80046
dc.identifier.doi10.1002/cpt.1959
dc.description.abstract

This article is protected by copyright. All rights reserved. The platelet endothelial aggregation receptor-1 (PEAR1) rs12041331 variant has been identified as a genetic determinant of platelet aggregation in response to antiplatelet therapies, including aspirin. However, association with atherothrombotic cardiovascular events is less clear, with limited evidence from large trials. Here, we tested association of rs12041331 with cardiovascular events and aspirin use in a randomized trial population of healthy older individuals. We undertook post-hoc analysis of N=13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, median age 74 years. Participants had no previous diagnosis of atherothrombotic cardiovascular disease at enrolment, and were randomized to either 100 mg daily low-dose aspirin or placebo for median 4.7 years follow-up. We used Cox proportional hazard regression to model the relationship between rs12041331 and the ASPREE primary cardiovascular disease endpoint (CVD), and composites of major adverse cardiovascular events (MACE) and ischaemic stroke (STROKE); and bleeding events; major hemorrhage (MHEM) and intracranial bleeding (ICB). We performed whole-population analysis using additive and dominant inheritance models, then stratified by treatment group. Interaction effects between genotypes and treatment group were examined. We observed no statistically significant association (P<0.05) in the population, or by treatment group, between rs12041331 and cardiovascular or bleeding events in either model. We also found no significant interaction effects between rs12041331-A and treatment group, for CVD (P=0.65), MACE (P=0.32), STROKE (P=0.56), MHEM (P=0.59) or ICB (P=0.56). The genetic variant PEAR1 rs12041331 is not associated with cardiovascular events in response to low-dose aspirin in a healthy elderly population.

dc.languageeng
dc.relation.sponsoredbyhttp://purl.org/au-research/grants/nhmrc/334047
dc.relation.sponsoredbyhttp://purl.org/au-research/grants/nhmrc/1127060
dc.subjectGenetics
dc.subjectaspirin
dc.subjectcardiovascular disease
dc.subjectplatelet aggregation
dc.titleGenetic variation in PEAR1, cardiovascular outcomes and effects of aspirin in a healthy elderly population
dc.typeJournal Article
dcterms.source.issn0009-9236
dcterms.source.titleClinical Pharmacology and Therapeutics
dc.date.updated2020-07-16T03:45:04Z
curtin.departmentSchool of Public Health
curtin.accessStatusFulltext not available
curtin.facultyFaculty of Health Sciences
curtin.contributor.orcidReid, Christopher [0000-0001-9173-3944]
dcterms.source.eissn1532-6535
dc.date.embargoEnd2021-06-21


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record